Nitric Oxide News and Research

RSS

Study confirms that COX-2 inhibitors predispose people to cardiovascular disease

After nearly 13 years of study and intense debate, a pair of new papers from the Perelman School of Medicine, at the University of Pennsylvania have confirmed exactly how a once-popular class of anti-inflammatory drugs leads to cardiovascular risk for people taking it.

3 May 2012

Gas NO plays a fundamental regulatory role in controlling bacterial function

Bacteria provide a well-known playground for scientists and the evolution of these earliest life forms has shed important perspective on potential therapies for some of the most common, deadly diseases. Researchers at Case Western Reserve University School of Medicine have now discovered that, the gas nitric oxide (NO), produced in all cells of the human body for natural purposes, plays a fundamental regulatory role in controlling bacterial function, via a signaling mechanism called S-nitrosylation (SNO), which binds NO to protein molecules.

27 Apr 2012

Helpful roles of rank, toxic substances

Usually, we think of mold, feces, nitric oxide, hydrogen sulfide and rat poison as rank, toxic or both. But scientists funded by the National Institutes of Health are learning more about the helpful roles these substances can play.

26 Apr 2012

Physical activity reduces oxidative stress in people with SCT

Sickle cell disease (SCD), an inherited condition that causes red blood cells to sometimes deform into a crescent shape, affects an estimated 100,000 Americans, typically those of African descent. However, far more have sickle cell trait (SCT), caused when individuals carry just a single copy of the disease-causing mutation in their genes.

26 Apr 2012

Bedfont Scientific Ltd Agree the acquisition of Logan Research Ltd

Bedfont has agreed the acquisition of Logan Research Ltd in a deal to move the company into a new area of scientific applications for breath research.

From Bedfont® Scientific Ltd 25 Apr 2012

TGA approves Ikaria’s LUCASSIN to treat Hepatorenal Syndrome Type 1

Ikaria, Inc., a critical care company focused on developing and commercializing innovative therapies for critically ill patients, announced today the approval of LUCASSIN (terlipressin) by the Therapeutic Goods Administration (TGA) of Australia.

24 Apr 2012

Study determines importance of bacterial infections in cirrhosis

A South African study presented today determines the importance of bacterial infections, which commonly occur in cirrhosis and can alter the natural history of the condition, possibly leading to loss of liver function and decompensation. It is now recognised that many infections in cirrhotic patients result from bacterial translocation (BT) from the intestine.

20 Apr 2012

ACAAI/AAAAI publish position statement in support of ATS guideline on Aerocrine's FeNO test

Aerocrine AB announces that a nine-member council representing both prestigious asthma societies, the American Academy and the American College of Allergy, Asthma and Immunology (ACAAI and AAAAI), have published a position statement in support of the clinical practice guideline on Aerocrine's FeNO test as published by the ATS.

2 Apr 2012

Local air pollution may explain neighborhood differences in rates of childhood asthma

Where a child lives can greatly affect his or her risk for asthma. According to a new study by scientists at Columbia University, neighborhood differences in rates of childhood asthma may be explained by varying levels of air pollution from trucks and residential heating oil. Results appear online in the Journal of Exposure Science and Environmental Epidemiology.

28 Mar 2012

Klf4 protein an important regulator of inflammation: HNK study

Microglia are the first line defence of the brain and are constantly looking for infections to fight off. Overactive microglia can cause uncontrolled inflammation within the brain, which can in turn lead to neuronal damage. New research published in BioMed Central's open access journal Journal of Neuroinflammation shows that, honokiol (HNK) is able to down-regulate the production of pro-inflammatory cytokines and inflammatory enzymes in activated microglia via Klf4, a protein known to regulate DNA.

19 Mar 2012

BC BS of Florida retires negative medical policy for FeNO testing

Aerocrine AB announces that BlueCross BlueShield (BC BS) of Florida1 has retired/archived their negative medical policy for FeNO testing. The change is effective March 15, 2012.

17 Mar 2012

Positive results from Bausch + Lomb, NicOx BOL‑303259‑X phase 2b study on OAG

Bausch + Lomb, the global eye health company, and NicOx S.A. today announced positive top-line results from the phase 2b study conducted with BOL‑303259‑X, a novel nitric oxide-donating prostaglandin F2‑alpha analog, in patients with open-angle glaucoma or ocular hypertension.

13 Mar 2012

Many premature infants continue to receive iNO during NICU stay

Many premature infants throughout the United States continue to receive inhaled nitric oxide (iNO) during their NICU stay, despite the lack of evidence to support its use. Whether or not a preemie will receive iNO treatment, when and for how long, varies greatly throughout the country, as its use in premature infants appears to be unstandardized.

13 Mar 2012

UHC retires negative coverage policy effective April 1, 2012

Aerocrine AB announces that United Healthcare has retired its negative coverage policy effective April 1, 2012.

12 Mar 2012

New hybrid aspirin shrinks tumors, curbs cancer cell growth

The humble aspirin may soon have a new role. Scientists from The City College of New York have developed a new aspirin compound that has great promise to be, not only an extremely potent cancer-fighter, but even safer than the classic medicine cabinet staple.

9 Mar 2012

Inhalation of nitric oxide could help improve blood flow to ischemic brain

LMU researchers developed a new strategy for the treatment of stroke, which could help to improve blood flow to ischemic brain. Strokes are due to a localized reduction in the blood supply to the brain, mainly due to the blockage of a vessel by a blood clot.

5 Mar 2012

New NOSH-aspirin appears more effective against cancer

Scientists have combined two new "designer" forms of aspirin into a hybrid substance that appears more effective than either of its forebears in controlling the growth of several forms of cancer in laboratory tests. Their report on the new NOSH-aspirin, so named because it releases nitric oxide (NO) and hydrogen sulfide (H2S), appears in the journal ACS Medicinal Chemistry Letters.

29 Feb 2012

Enrollment complete in Ikaria iNO Pivotal Phase III trial for BPD

Ikaria, Inc., a critical care company focused on developing and commercializing innovative therapies for critically ill patients, today announced that it has enrolled the last patient into its Pivotal Phase III trial investigating the use of inhaled nitric oxide (iNO) in premature infants with bronchopulmonary dysplasia (BPD).

27 Feb 2012

Tetrahydrobiopterin plays a key role in arterial health of women

Researchers studying why arteries stiffen in postmenopausal women have found a specific chemical cofactor that dramatically improves vascular function.

15 Feb 2012

Ikaria receives FDA orphan drug designation for use of iNO in PAH

Ikaria, Inc., a critical care company focused on developing and commercializing innovative therapies for critically ill patients, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for the use of inhaled nitric oxide (iNO) with the INOpulse DS drug-delivery system as a combination product for pulmonary arterial hypertension.

23 Jan 2012